Xbrane Biopharma
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
XBRANE | ST
Overview
Corporate Details
- ISIN(s):
- SE0007789409 (+1 more)
- LEI:
- 5493008DKD05APTKQO39
- Country:
- Sweden
- Address:
- RETZIUS VÄG, 8, 171 65 Solna
- Website:
- https://xbrane.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Xbrane Biopharma is a biotechnology company specializing in the development of biosimilars, which are affordable, follow-on versions of approved biological drugs. The company's mission is to increase global access to treatments for serious diseases such as cancer, rheumatoid arthritis, and macular degeneration. Xbrane leverages a patented, high-yield production platform technology designed to significantly reduce manufacturing costs, aiming for up to an 80% cost reduction compared to standard systems. Its development portfolio includes biosimilar candidates targeting major biologic drug markets, such as Xlucane™ (a ranibizumab biosimilar) and BIIB801 (an adalimumab biosimilar).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-05 10:52 |
Major Shareholding Notification
|
Swedish | 10.0 KB | ||
| 2025-11-03 08:35 |
Declaration of Voting Results & Voting Rights Announcements
ANTALET AKTIER OCH RÖSTER I XBRANE HAR FÖRÄNDRATS TILL FÖLJD AV TIDIGARE OFFENT…
|
Swedish | 67.6 KB | ||
| 2025-11-03 08:35 |
Declaration of Voting Results & Voting Rights Announcements
THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOU…
|
English | 67.1 KB | ||
| 2025-10-24 08:00 |
Quarterly Report
|
Swedish | 859.8 KB | ||
| 2025-10-24 08:00 |
Quarterly Report
|
English | 855.9 KB | ||
| 2025-10-20 08:00 |
Board/Management Information
XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE
|
English | 60.9 KB | ||
| 2025-10-20 08:00 |
Board/Management Information
XBRANE BIOPHARMA PRESENTERAR VALBEREDNINGEN
|
Swedish | 60.3 KB | ||
| 2025-10-19 20:00 |
Legal Proceedings Report
Xbrane provides Regulatory update on FDA review of its ranibizumab biosimilar c…
|
English | 69.0 KB | ||
| 2025-10-19 20:00 |
Legal Proceedings Report
Xbrane ger regulatorisk uppdatering om FDA:s granskning av dess ranibizumab-bio…
|
Swedish | 68.9 KB | ||
| 2025-10-16 18:05 |
Capital/Financing Update
Xbrane Biopharma ingår villkorad finansieringslösning med Fenja Capital II A/S
|
Swedish | 70.7 KB | ||
| 2025-10-16 18:05 |
Capital/Financing Update
Xbrane Biopharma enters into conditional financing solution with Fenja Capital …
|
English | 71.0 KB | ||
| 2025-10-15 16:15 |
Share Issue/Capital Change
Record date for reverse share split in Xbrane Biopharma AB
|
English | 60.1 KB | ||
| 2025-10-15 16:15 |
Share Issue/Capital Change
Avstämningsdag för sammanläggning av aktier i Xbrane Biopharma AB
|
Swedish | 59.7 KB | ||
| 2025-10-13 11:45 |
Post-Annual General Meeting Information
Announcement from extra general meeting in Xbrane Biopharma AB
|
English | 66.7 KB | ||
| 2025-10-13 11:45 |
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
|
Swedish | 66.7 KB |
Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xbrane Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-17 | Karl Martin Erik Åmark | Other | Buy | 1,864,223 | 318,782.13 SEK |
| 2025-01-17 | Karl Martin Erik Åmark | Other | Sell | 1,864,223 | 315,053.69 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Sell | 1,519,932 | 260,212.36 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Buy | 1,500,000 | 256,500.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Buy | 4,000 | 129,000.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Sell | 4,000 | 128,200.00 SEK |
| 2023-09-11 | Karl Martin Erik Åmark | Other | Sell | 2,000 | 62,140.00 SEK |
| 2023-09-08 | Siavash Bashiri | Other | Sell | 5,890 | 194,959.00 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | 968.54 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | N/A |
